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A specific activity-based probe to monitor family GH59 
galactosylceramidase  the enzyme deficient in Krabbe disease
André R. A. Marques[a],[f],, Lianne I. Willems[b],[g],, Daniela Herrera Moro[a], Bogdan I. Florea[b], Saskia 
Scheij[a], Roelof Ottenhoff[a], Cindy P. A. A. van Roomen[a], Marri Verhoek[c], Jessica K. Nelson[a], 
Wouter W. Kallemeijn[c], Anna Biela-Banas[d], Olivier R. Martin[d], M. Begoña Cachón-González[e], Nee 
Na Kim[e], Timothy M. Cox[e], Rolf G. Boot[c], Herman S. Overkleeft*[b] and Johannes M. F. G. Aerts*[a],[c]
Abstract: Galactosylceramidase (GALC) is the lysosomal β-
galactosidase responsible for the hydrolysis of galactosylceramide. 
Inherited deficiency in GALC causes Krabbe disease, a devastating 
neurological disorder characterized by accumulation of 
galactosylceramide and its deacylated counterpart, the toxic 
sphingoid base galactosylsphingosine (psychosine). We report the 
design and application of a fluorescently tagged activity-based probe 
(ABP) for the sensitive and specific labeling of active GALC 
molecules from various species. The probe consists of a β-
galactopyranose-configured cyclophellitol-epoxide core, conferring 
specificity for GALC, equipped with a Bodipy fluorophore at C6 that 
allows visualizing active enzyme in cells and tissues. The detection 
of residual GALC in patient fibroblasts holds great promise for 
laboratory diagnosis of Krabbe disease. We further describe a 
procedure for in situ imaging of active GALC in murine brain by 
intracerebroventricular infusion of the ABP. In conclusion, the GALC-
specific ABP should find broad applications in diagnosis, drug 
development and evaluation of therapy of Krabbe disease.
Introduction
Glycoside hydrolase family 59 (GH59) human 
galactosylceramidase (GALC, galactocerebrosidase) is an 80-
kDa protein responsible for the lysosomal turnover of 
galactosylceramide and galactosylsphingosine. Newly 
synthesized GALC contains at least four N-linked glycosylation 
sites which are responsible for lysosomal trafficking via the 
mannose-6-phosphate receptor.
[1]
After entering the lysosomes, 
the enzyme is cleaved into 30- and 50-kDa subunits without 
effect on enzymatic activity.
[2]
Crystal studies indicate that no 
dissociation of these subunits occurs.
[3]
 Substrate hydrolysis by 
GALC occurs through a Koshland double displacement 
mechanism with overall retention of the β-anomeric configuration 
of the released galactopyranoside (Figure 1A). The two 
carboxylic acid residues in the active site that function as a 
nucleophile and a general acid/base have been identified as the 
glutamic acid residues E258 and E182, respectively.
[1,3]
Deficiencies in GALC are at the basis of the autosomal 
recessive lysosomal storage disorder Krabbe disease, also 
termed globoid cell leukodystrophy. More than 70 mutations in 
the gene encoding GALC have been implicated in the 
development of this disease.
[1]
The main pathological 
consequences are found in the peripheral and central nervous 
system. The mechanism behind this neuropathology has not yet 
been fully elucidated.
[1,2]
Reduced activity of GALC results in a 
reduced catabolism of galactosphingolipids including 
galactosylceramide and galactosylsphingosine (psychosine). 
Galactosylceramide is the main lipid component of myelin, the 
protective sheath around neuron axons and essential for correct 
functioning of the nervous system. Accumulation of the toxic 
metabolite galactosylsphingosine eventually leads to apoptosis 
of myelin-forming cells and consequently demyelination and 
neurodegeneration.
[4,5]
Infantile Krabbe disease is usually 
diagnosed before one year of age and lethal before the age of 
two. Early symptoms include limb stiffness, developmental delay, 
and severe irritability. When diagnosed in adolescents or adults 
other symptoms may be observed such as seizures, feeding 
difficulties, slowing of mental and motor development, muscle 
weakness, spasticity, deafness, and blindness. The onset and 
severity of symptoms as well as the course of the disease in 
adult Krabbe patients is highly variable, even in patients carrying 
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Figure 1. Galactocerebrosidase and structures of inhibitors and probes 1-7. A) Mechanism of substrate hydrolysis by GALC. B) Proposed mechanism of GALC 
binding by compounds 1-4. C) Structures of novel retaining β-galactosidase inhibitor 1 and ABPs 2-4. β-Glucopyranosyl-configured compound 5 targets 
glucocerebrosidase. ABB166 (6)
[31]
and galactosylsphingosine (psychosine, 7) are competitive GALC inhibitors.
the same mutation.
[6,7]
Diagnosis can be confirmed by measuring 
residual GALC activity in leukocytes or cultured skin fibroblasts, 
which is usually 0-5% of normal levels. However, the amount of 
residual activity is neither directly correlated to the clinical 
symptoms nor to the course of the disease. Carriers may have 
as little as 10-20% of normal GALC activity without being 
affected. The only available treatment for Krabbe disease 
involves symptomatic treatment and physical therapy. Clinical 
trials with hematopoietic stem cell transplantation, which aim to 
restore GALC activity in the central nervous system and thereby 
prevent further demyelination, hold promise in slowing the 
course of juvenile Krabbe disease when diagnosed at an early 
stage.
[8,9]
Further investigations of GALC and its involvement in 
Krabbe disease would benefit from the availability of an activity-
based probe (ABP) that specifically targets this enzyme. 
Numerous fluorescent β-galactosidase probes have been 
reported in literature. However, most of these are reversible and 
can therefore not be used in, for example, gel-based assays. 
Examples include substrates consisting of a β-galactose moiety 
with a luminescent or fluorogenic tag attached to the aglycon 
position that is released after cleavage by the enzyme,
[10-16]
and 
fluorescently tagged competitive inhibitors.
[17,18]
In addition, a few 
ABPs that enable non-reversible mechanism-based labeling of 
retaining β-galactosidases have been reported. These include 
suicide substrates bearing a latent quinone methide precursor 
as the aglycon to which a fluorescent or fluorogenic tag is 
attached
[19–22]
and 2-fluorogalactoside inhibitors in which the 
hydroxyl group at C6 is substituted with an azide, which enables 
two-step labeling via Staudinger-Bertozzi ligation.
[23]
To date, 
none of these probes has been used for the labeling of human 
retaining β-galactosidases.
Our work on activity-based retaining glycosidase probes 
uses the natural product and retaining β-glucosidase inhibitor, 
cyclophellitol, as starting point.
[24]
 Substituting the epoxide for an 
aziridine and grafting a reporter group onto the aziridine nitrogen 
yields ABPs broadly selective for various members within a 
given class of retaining glycosidases. Glycosidase family-
selectivity is dictated by the configuration of the cyclophellitol 
aziridine derivative, an approach that was shown valid for GH1 
retaining β-glucosidases, GH79 retaining α-galactosidases and, 
most recently, for GH29 retaining α-fucosidases.
[25–27]
In our first 
forays into activity-based glycosidase profiling, however, we 
studied cyclophellitol derivatives modified at C6 (glucopyranose 
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numbering) with a fluorophore.
[28]
These epoxide probes exhibit 
much higher selectivity than their aziridine analogues. Because 
of their high selectivity and potency for human lysosomal 
glucosylceramidase (GBA) – the enzyme deficient in Gaucher 
patients – we now routinely use the fluorescent cyclophellitol 
derivatives to monitor GBA activity in vitro, in situ and in vivo in 
healthy and Gaucher models.
[28]
We realized that this probe design might also hold 
potential for the development of a GALC ABP suitable for 
monitoring this enzyme in the context of Krabbe disease (Figure 
1B), the more so since GALC and GBA have related 
glycosylceramide substrates. Here we describe the evaluation of 
β-galactopyranose-configured epoxides 1-4 as inhibitors and 
ABPs for GALC (Figure 1C). The cyclophellitol core of these 
probes, synthesized as reported,
[24,29,30]
was designed to mimic 
the substrate’s terminal galactosyl moiety and bind covalently to 
the target enzyme via nucleophilic attack of the catalytic residue 
in the active site on the β-configured electrophilic epoxide moiety 
(Figure 1B). The non-tagged inhibitor 1 was included in our 
studies as a galactose-configured isomer of the known retaining 
β-glucosidase inhibitor cyclophellitol.
[24,28]
For potential use in 
two-step activity based profiling studies, in ABP 2 the primary 
hydroxyl group is substituted with an azide that can be used for 
two-step labeling via copper(I)-catalyzed or copper-free strain 
promoted alkyne-azide [2+3] cycloaddition chemistry or 
Staudinger-Bertozzi ligation. In addition, this probe may serve as 
a control probe and an inhibitor. ABPs 3 and 4 were obtained by 
functionalization of 2 with a Bodipy fluorophore and a biotin tag, 
respectively.
Results 
Labeling and inhibition of recombinant 
galactocerebrosidase
First we evaluated the ability of compounds 1-4 to inhibit 
recombinant galactocerebrosidase (GALC) by measuring 
residual enzyme activity using the fluorogenic substrate 4-
methylumbelliferyl β-D-galactopyranoside (4-MU β-Gal) after 30 
min of pre-incubation with varying concentrations of the probes. 
Plots of residual activity against inhibitor concentration reveal a 
clear dose-dependent inhibition of GALC by all probes (Figure 
2A). The apparent IC50 values calculated from these curves are 
shown in Table 1. The non-tagged epoxide 1 proved to be a very 
potent inhibitor of GALC with an apparent IC50 value of 38 nM. 
Substitution of the hydroxyl group at the C6 position with an 
azide (2), however, resulted in a dramatic loss of potency with 
an almost 2000-fold increase of the apparent IC50 value (70 µM). 
We found probe 2 to reach full inhibition after a prolonged 
incubation time. Interestingly, the inhibitory potency was partially 
restored by incorporation of a Bodipy dye (3), but not a biotin tag 
(4), at the same position. The second order rate constants for 
inhibition (ki/Ki) of compounds 1 and 3 were in agreement with 
this observation (see Table 1 and Supporting Figure 1). Hence, 
it appears that the hydrophobic fluorophore leads to enhanced 
binding of the probe to its target enzyme and might be better 
tolerated in the active site of the enzyme than a small polar 
azide moiety. A similar result has been found previously for the 
inhibition of retaining β-glucosidases by analogous C6-modified 
probes, although the beneficial effect of the Bodipy dye was 
much larger in that case.
[28]
On the contrary, previous findings 
suggest that neither of the α-configured isomers of the C6-
functionalized epoxide probes 2-4 appears to inhibit retaining α-
galactosidases,
[26]
indicating that this phenomenon is dependent 
on the specific active site features and substrate tolerance of 
each individual glycosidase.
To demonstrate the non-reversibility of GALC inhibition by 
ABP 3 we pre-incubated GALC with ABP 3 for different time
periods. Next, residual enzymatic activity in the samples was 
determined and aliquots of the same samples were subjected to 
gel electrophoresis to quantify ABP-labeled GALC (Supporting 
Figure 2). Enzyme activity was irreversibly lost during the pre-
incubation in time- and concentration-dependent manner. Loss 
of activity of GALC by pre-incubation with ABP 3 correlated with 
its fluorescent labeling. To further demonstrate irreversibility of 
labeling, we incubated GALC with ABP 3 for one hour and 
separated enzyme and small compound using a spin dialysis 
cartridge with 7 kDa cutoff. No activity was found to be 
recovered over time after removal of free unbound ABP 3 from 
the enzyme (Supporting Figure 3). We also incubated enzyme 
and ABP 3 briefly (2 min) before performing the same 
separation: in this case part of the separated enzyme population 
was still active. Again, the amount of enzyme activity did not 
increase following the separation from free ABP 3. Analysis of 
labeled GALC revealed no loss of label following separation of 
pre-labeled enzyme from free ABP 3 (Supporting Figure 3). In 
order to assess the selectivity of inhibitors 1-4 for retaining β-
galactosidases over the related class of retaining α-
galactosidases, we determined inhibition of recombinant α-
galactosidase A (Fabrazyme) by using a similar assay with the 
fluorogenic substrate 4-methylumbelliferyl α-D-galactoside. We 
did not detect any inhibition after 30 min of pre-incubation with 
up to 100 µM of the probes (data not shown).
Having shown that compounds 1-4 are able to irreversibly 
inhibit GALC, we next assessed the visualization of the 
recombinant enzyme on gel using fluorescently labeled ABP 3. 
Table 1. Inhibition of recombinant galactocerebrosidase activity.
Compound Apparent ki/Ki Percentage inhibition (%)
IC50 (µM)
[a]
(µM
-1
min
-1
) 30 min 6 hrs
Epoxide 1 0.038 12.06 98 (1 µM) 100 (1 µM)
Azido-epoxide 2 70 N.A. 62 (100 µM) 96 (100 µM)
Bodipy-epoxide 3 2.8 0.014 97 (100 µM) 100 (100 µM)
Biotin-epoxide 4 30 N.A. 81 (100 µM) 97 (100 µM)
[a] Inhibition of recombinant GALC as determined from hydrolysis of 4-MU β-
gal after pre-incubation for 30 min or 6 h with probes 1-4. Apparent IC50 values 
were calculated from residual GALC activity as a function of probe 
concentration (Figure 2A). Second order rate constants were calculated from 
progress curves over time (Supporting Figure 1).
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Figure 2. Labeling and inhibition of recombinant GALC. A) Inhibition of recombinant GALC activity. Recombinant GALC was treated for 30 min with inhibitors 1-4
after which residual activity was determined from hydrolysis of 4-MU β-gal. B) Labeling with 0.01 - 10 µM of Bodipy-epoxide 3 for 1 h; where indicated enzyme 
was denatured prior to labeling by boiling at 100°C for 3 min in assay buffer (+) or in buffer with 1% SDS (+SDS). C) Labeling with 0.2 µM 3 after pre-incubation 
with inhibitors 1 (0.2 µM), 2 (10 µM) or 4 (10 µM) for 1 hr. D) Labeling with 0.1 - 10 µM of biotin-epoxide 4 for 1 h; where indicated enzyme was denatured prior to 
labeling by boiling at 100°C for 3 min. E) Recombinant GALC was labeled with 0.5 µM 3 for 1 h in buffers of varying pH. Samples were analyzed by 10% SDS-
PAGE with fluorescent readout followed by Coomassie brilliant blue (CBB) staining (B, C, E) or streptavidin western blotting (D). M: protein marker. F) 
Quantification of gel bands in A (circles) as compared to GALC activity on 4-Mu β-Gal (triangles) at different pH values. G) Selective labeling of retaining β-
galactosidases and retaining β-glucosidases with differently configured epoxide ABPs. Recombinant GALC and glucocerebrosidase (GBA) were labeled with 1 
µM of ABP 3 or ABP 5 for 1 h and labeled proteins were resolved by 7.5% SDS-PAGE with fluorescent readout.
Exposure to Bodipy-epoxide 3 for 1 h resulted in concentration-
dependent fluorescent labeling of a band around 80 kDa, 
corresponding to the molecular weight of non-dissociated GALC 
(Figure 2B). The labeling was completely abolished by 
denaturation of the enzyme prior to addition of the ABP, 
confirming the specific binding of the probe to catalytically active 
enzyme. In addition, a second fluorescently labeled band of 
approximately 60 kDa was visible at higher probe concentrations. 
This protein most likely represents serum albumin, a component 
of the cell culture medium. Unwanted labeling of albumin by 
Bodipy-functionalized probes can be caused by non-specific 
interactions of the hydrophobic dye with the protein. Evidence 
for the non-specific nature of these interactions is provided by 
the fact that denaturation of the protein by boiling in assay buffer 
prior to labeling with ABP 3 resulted in an even stronger 
fluorescent signal, which could only be eliminated by addition of 
the surfactant SDS.
Pre-treatment of samples with non-tagged inhibitor 1 led to 
complete disappearance of the fluorescent labeling of GALC by 
Bodipy-tagged epoxide 3, while the labeling of albumin was 
unaffected (Figure 2C). Pre-incubation with azide- and biotin-
tagged probes 2 and 4 resulted in partial blocking of the 
fluorescent labeling of GALC. We also used biotinylated ABP 4
to visualize GALC activity directly by streptavidin western 
blotting (Figure 2D). In agreement with the higher IC50 value of 
this probe as compared to its fluorescently labeled analogue 3, a 
relatively large amount of probe is required to label the enzyme. 
At the highest concentration tested (10 µM) a single biotin-
labeled band was clearly visible that corresponds to catalytically 
active GALC.
pH-dependence of galactocerebrosidase labeling
Since GALC is a lysosomal enzyme, its activity is highest in a 
slightly acidic environment with an optimum around pH 4.3.
[3]
We 
examined the pH-dependence of GALC labeling by Bodipy-
functionalized ABP 3 by exposing the recombinant enzyme to 
the probe in buffers of varying pH (Figure 2E). The intensity of 
fluorescent labeling of GALC is highest at pH 4-5 while it is 
almost completely abolished at pH 3 and lower or pH 7 and 
higher. Quantification of the fluorescent gel bands revealed that 
the amount of labeling by ABP 3 overlaps perfectly with the 
enzymatic activity as determined by fluorogenic substrate 
hydrolysis (Figure 2F). These results indicate that binding of the 
probe occurs in an activity-based manner and support the 
proposed binding mechanism depicted in Figure 1B.
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Figure 3. Labeling of tissues of wt, GALC-deficient (Twitcher) and heterozygous mice. A) Homogenates of brain, kidney, sciatic nerve and liver of wt (Galc+/+), 
carrier (Galc+/-), and Twitcher (Galc-/-) mice were incubated with ABP 3 (1 µM) or ABP 5 (100 nM). Samples were analyzed by 7.5% SDS-PAGE with fluorescent 
readout followed by Coomassie brilliant blue (CBB) staining. M: protein marker. B) Competition of ABP 3 labeling of GALC in mouse kidney and brain 
homogenates by ABB166 (6) and psychosine (7). C) Kidney homogenates were pre-incubated with 10 µM ABP 3 and 0.5 µM compound 1 for 1 h, after which the 
residual acid β-galactosidase and GALC enzyme activity was determined. D) Brain homogenates were pre-incubated with 10 µM ABP 3 and 0.5 µM inhibitor 1 for 
1 h, after which the residual acid β-galactosidase and GALC enzyme activity was determined. Data (n = 3 per group, mean ± SD) were analyzed using one-way 
ANOVA followed by the Dunnetts multiple comparison test: * P < 0.05; ** P < 0.01; *** P < 0.001.
Selectivity of galactocerebrosidase labeling
Next we set out to validate our hypothesis that selective labeling 
of retaining β-galactosidases and retaining β-glucosidases can 
be achieved with differently configured epoxide-based ABPs. 
For this purpose, we used β-galactosidase ABP 3 and the 
previously reported β-glucosidase ABP 5
[28]
(Figure 1C) to label 
either recombinant GALC or recombinant glucocerebrosidase, a 
lysosomal retaining β-glucosidase. The two ABPs are 
functionalized with different Bodipy fluorophores and can 
therefore be visualized using different scanner settings for in-gel 
fluorescent readout. While GALC was labeled exclusively by 
probe 3, glucocerebrosidase was labeled by ABP 5 but not by its 
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stereoisomer 3 (Figure 2G). The absence of cross-reactivity 
demonstrates the selective targeting of each of these enzymes 
by the appropriately configured ABPs.
To further demonstrate the specificity of probe 3 towards 
GALC and to show its application to label endogenous enzyme 
we used the probe to label various tissue extracts of Twitcher 
(twi/twi) mice.
[32]
These animals are a naturally occurring model 
of Krabbe disease and lack GALC protein. We compared the 
labeling of tissues of wild-type (wt), Twitcher and heterozygous 
mice with ABP 3 and ABP 5. As expected, labeling by β-
glucosidase probe 5 occurred in all tissues of all the genotypes 
(Figure 3A). However, incubation of tissue lysates with GALC 
probe 3 resulted in fluorescent labeling of a single band of 
approximately 50 kDa in the kidney, brain and sciatic nerve of wt 
and heterozygous animals but not of Twitcher mice (Figure 3A). 
This band corresponds to the 50 kDa subunit of GALC that is 
formed after proteolytic cleavage of the enzyme in the lysosome. 
The fact that no labeling by probe 3 was detected in wt liver is in 
line with the low expression levels of GALC in this organ.
[33]
To 
confirm the identity of the labeled proteins, we performed a 
streptavidin affinity purification after labeling of mouse kidney 
lysates with biotinylated ABP 4. Proteins were subjected to LC-
MS/MS identification following tryptic digestion. Analysis of those 
proteins specifically enriched in samples treated with probe as 
compared to the no-probe control reveals the specific labeling of 
several peptides from the N-terminal part of the active 50 kDa 
GALC protein by ABP 4 (see Supporting Table 1).
Next, we studied competition of ABP 3 labeling of GALC 
by two known competitive inhibitors of the enzyme, ABB116
[31]
(Figure 1C, compound 6) and galactosylsphingosine or 
psychosine (Figure 1C, compound 7). Labeling of GALC in 
mouse brain and kidney lysates by probe 3 was fully competed 
by both inhibitors at millimolar concentration, confirming that the 
ABP binds to the active site of the enzyme (Figure 3B).
Besides GALC lysosomes contain another acid β-
galactosidase involved in degradation of various substrates like 
ganglioside GM1, lactosylceramide, glycoproteins and keratan 
sulfate-derived oligosaccharides.
[3436]
Malfunctioning of this β-
galactosidase can cause GM1 gangliosidosis and Morquio B 
syndrome.
[34,37]
To evaluate the enzyme specificity of probe 3
and the epoxide inhibitor 1 within the family of retaining β-
galactosidases, we investigated their effect on the enzymatic 
activity of lysosomal acid β-galactosidase and GALC. To 
distinguish the two enzyme activities we followed the protocol 
described by Martino et al. which employs AgNO3 as a selective 
competitive inhibitor of lysosomal acid β-galactosidase.
[38]
Pre-
incubation of brain and kidney lysates with 10 µM of probe 3
resulted in significant decrease of GALC activity (approximately 
50% of untreated values) in these tissues, while β-galactosidase 
activity was unaltered (Figure 3C and D). In contrast, incubation 
of the lysates with 0.5 µM of inhibitor 1 completely abrogated 
both enzyme activities.
The human body contains one additional β-galactosidase 
in the small intestine, lactase, also known as lactase-phlorizin 
hydrolase (LPH).
[39,40]
This enzyme, which also has β-
glucosidase activity, cleaves lactose into galactose and glucose 
and deficiency in its activity causes lactose-intolerance. We 
transfected HEK293 cells with LPH and studied labeling of the 
enzyme by ABP 3 and ABP 5 using a concentration of this probe 
at which it is known to target LPH (Supporting Figure 4).
[28]
Whilst the β-glucosidase ABP 5 gave prominent labeling of LPH, 
this was negligible for ABP 3, again indicating specificity of ABP 
3 for binding to GALC and not LPH.
In situ and in vivo GALC labeling
Finally, we examined labeling of GALC by ABP 3 in intact cells 
and tissues. We noted earlier that the stereoisomer ABP 5 is 
able to penetrate cells by diffusion and efficiently labels 
lysosomal glucocerebrosidase in situ.
[28]
Cultured HEK293 cells, 
with and without overexpression of GALC, were exposed for 1 
hour to 5 nM ABP 3 and confocal fluorescence microscopy was 
used to detect labeled GALC in the non-fixed cells. The 
fluorescent labeling in control HEK293 cells was low (Figure 4A), 
in agreement with the virtual absence of endogenous GALC 
labeling in HEK cells extracts (see Supporting Figure 4). Low 
expression levels of GALC were further confirmed by western 
blot (not shown). However, in cells overexpressing GALC a 
perinuclear vesicular labeling, characteristic for lysosomes, was 
observed (Figure 4A). The perinuclear vesicular labeling pattern 
of lysosomes was confirmed by labeling of fixed cells with the 
lysosomal marker LAMP1 (Figure 4A, last panel).
Next, we examined ABP 3 labeling of endogenous GALC 
in the brain of living mice. For this purpose, we 
intracerebroventricularly infused mice for 2 hours with 1 nM ABP 
3. The animals were sacrificed and brain slices were examined 
by confocal fluorescence microscopy. Pronounced perinuclear 
labeling was detected in cells of the cerebellar cortex, 
overlapping with immunohistochemical detection of GALC and 
lysosomal marker LAMP1 (Figure 4B).
To investigate the potential of ABP 3 for the diagnosis of 
Krabbe disease, we labeled fibroblasts from Gaucher and 
Krabbe disease patients and healthy volunteers simultaneously 
with ABP 3 and ABP 5. Labeling was preceded by an affinity 
purification of glycosylated proteins with Concanavalin A beads. 
A band of approximately 50 kDa corresponding to human GALC 
was labeled by ABP 3 in fibroblasts of the control subject and 
Gaucher disease patient (Figure 5), being virtually absent in 
samples from the individual diagnosed with Krabbe disease. As 
expected, active GBA labeled by ABP 5 was much less 
prominent in fibroblasts of Gaucher disease patient compared to 
the other cell types (Figure 5).
Discussion and conclusions
Prompted by the successful design of β-glucopyranose-
configured epoxide-based probes that are able to label 
lysosomal glucocerebrosidase (E.C. 3.2.1.45) in an activity-
based manner with high selectivity and sensitivity,
[28]
we 
examined a similar approach for the related enzyme 
galactocerebrosidase (GALC, E.C. 3.2.1.46). The β-
galactopyranose-configured epoxide-based probes 1-4 were 
demonstrated to inhibit recombinant and endogenous rodent 
GALC covalently and irreversibly. Of these probes, non-tagged 
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Figure 4. In situ labeling of GALC in intact cells in culture and in vivo in mouse brain. A) In situ labeling with ABP 3 of control HEK293 cells (top) and HEK293 
cells overexpressing GALC (bottom). Left to right: nuclear DAPI staining, ABP 3 labeling, and overlay of DAPI staining and ABP 3 labeling (all in non-fixed cells), 
and overlay of immuno-detection of lysosomal membrane marker LAMP1 and DAPI staining in fixed cells. Scale bars in third panels are 10 m, scale bars in right 
panels are 20 m. B) In vivo labeling with ABP 3 of wt mouse cerebellar cortex following i.c.v. administration. Left to right: DAPI staining, ABP 3 labeling, anti-
GalC Ab (top) or anti-LAMP1 Ab (bottom), and overlay of ABP 3 and Ab staining. Scale bar: 10 m.
epoxide inhibitor 1 is the most potent inhibitor. Substitution of the 
hydroxyl group at C6 with an azide (2) results in loss of potency, 
whereas installment of a Bodipy tag at the same position (3) 
partially restores the inhibitory potency. A high resolution crystal 
structure of murine GALC has recently been reported.
[3]
Soaking 
of crystalized enzyme with ABP 3 should yield an explanation for 
the noted differences in affinity of inhibitor 1 and ABPs 2-4.
Bodipy-functionalized ABP 3 and biotinylated ABP 4
enable the visualization of catalytically active GALC on gel. The 
epoxide probes label the enzyme in an activity-based manner. 
The selectivity of the labeling by ABP 3 is remarkable. In 
particular, Bodipy-epoxide 3 differs only in the configuration of a 
single substituent from the previously reported glucopyranose 
configured stereoisomer 5, yet the two probes enable selective 
targeting of GALC and glucocerebrosidase, respectively. At low 
concentrations, ABP 3 neither targets the related glycosidase α-
galactosidase A, and importantly none of the other retaining β-
galactosidases known to be present in humans, lysosomal acid
β-galactosidase (EC 3.2.1.24) and intestinal lactase-phlorizin 
hydrolase (LPH) (E.C. 3.2.1.106). Of note, we earlier noted the 
same high degree of selectively for Bodipy-functionalized β-
glucopyranose-configured epoxide 5.
[28]
At low concentration, 
this probe selectively labels lysosomal glucocerebrosidase but 
not the non-lysosomal glucosylceramidase GBA2, cytosolic β-
glucosidase GBA3 and LPH,
[28]
all other enzymes degrading 
glucosylceramide.
GALC is synthesized as precursor of about 80-kDa that is 
processed into 30- and 50-kDa fragments after lysosomal 
uptake. The two fragments do not dissociate but remain linked to 
each other via disulfide bridges.
[1]
The cleavage of the already 
active 80 kDa precursor does not affect the enzymatic activity.
[41]
In line with this, we found that recombinantly produced 80 kDa 
precursor GALC labels well with ABP 3. In lysates of GALC 
overexpressing HEK293 cells we could detect both 80 kDa 
precursor and the 50 kDa mature subunit with ABP 3 (data not 
shown). The 50 kDa GALC subunit, containing the catalytic 
nucleophile residue E258, is the major GALC form visualized 
with ABP 3 in kidney, brain and sciatic nerve of wt and 
heterozygous mice and is absent in the same tissues of Twitcher 
animals.
Importantly, the reported β-galactopyranose-configured 
epoxide-based probes can be applied as diagnostic tools in 
monitoring Krabbe disease by visualizing the levels of residual 
GALC activity, as was demonstrated here by the labeling of 
active enzyme in control compared to Krabbe disease fibroblasts. 
The probes may also be used in activity-based protein profiling 
studies, aiding in the development of novel therapeutic
strategies by facilitating the screening of potential chaperones
interacting with the catalytic pocket of GALC. Last but not least, 
the probes will likely prove of great value to evaluate efficacy of 
experimental therapies in mouse models of Krabbe disease.
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Figure 5. Labeling of Gaucher and Krabbe patient fibroblasts with ABPs 3 and 
5. Fibroblasts from Gaucher and Krabbe disease patients, and healthy 
volunteer were lysed and incubated overnight with Concanavalin A beads for 
enrichment of glycosylated proteins. Bead-bound GALC was labeled with ABP 
3 (1 M) followed by labeling of GBA with ABP 5 (0.1 M). Samples were 
resolved by 10% SDS-PAGE with fluorescent readout followed by Coomassie 
brilliant blue (CBB) staining. ‘M’: protein marker.
Experimental Section
Synthesis of β-galactopyranose-configured epoxide-based probes
The synthesis of β-galactopyranose-configured cyclophellitol epoxides 1-
4 has been reported.
[24]
Enzymes
Recombinant murine galactocerebrosidase (GALC) was expressed in 
human embryonic kidney 293 (HEK293) cells as previously described.
[1]
The mouse enzyme is 83% homologous to human GALC.
[1]
The culture 
medium containing the secreted recombinant protein was used directly 
for fluorogenic substrate assays and labeling assays. Recombinant α-
galactosidase A (Fabrazyme) and recombinant β-glucocerebrosidase 
(Cerezyme) were obtained from Genzyme.
Cells
Human embryonic kidney 293 (HEK293) cells (ATCC CRL 1573) were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) with high glucose 
(Gibco) supplemented with 10% FBS (Bodinco) and 100 units/mL 
penicillin/streptomycin (Gibco). HEK293 cells with and without stable 
over-expression of murine GALC were generated as previously 
described.
[1]
Animals
Twitcher mice (twi/twi), a natural model of Krabbe disease resulting from 
a mutation in the GALC gene, along with wild-type littermates were 
generated by crossing heterozygous (+/twi) mice in-house. The 
heterozygous C57BL/6J B6.CE-Galc
twi
/J mice (stock number 000845) 
were obtained from The Jackson Laboratory (Bar Harbor, USA). Mouse 
pups were genotyped as previously described.
[33]
Mice (± 3 weeks old) 
received the rodent AM-II diet (Arie Blok Diervoeders, Woerden, The 
Netherlands). Animals were housed and experiments were conducted 
according to approved protocol by the Institutional Animal Welfare 
Committee of the Academic Medical Centre Amsterdam in the 
Netherlands.
Twelve week-old wt C57Bl/6 mice were used for intracerebroventricular 
(i.c.v.) administration of ABP 3. The animals were kept in individual 
cages at constant temperature (23°C+/- 2 °C) and a 12/12h light/dark 
cycle. They were exposed to ad libitum food and water before and after 
the experimental procedures.
Fibroblasts
Fibroblasts were obtained from skin biopsies with informed and signed 
consent from the donors.
Expression and labeling of human lactase phlorizin hydrolase (LPH)
Primers were designed based on NCBI reference sequence 
NG_008104.2. Full-length cDNA sequence was cloned into pcDNA3.1 in 
frame with the myc/His vector (Invitrogen). Confluent HEK293 cells were 
transfected with empty pcDNA3.1 vector or the vector with the described 
insert, in conjunction with FuGENE (Roche), and harvested after 72 h by 
scraping in 25 mM potassium phosphate (KPi) buffer (pH 6.5, 
supplemented with 0.1% (v/v) Triton X-100 and protease inhibitor cocktail 
(Roche)). A volume equivalent to 50 µg of protein was labeled with 1 µM 
(final concentration) of ABP 3 or ABP 5 for 2 h at 37°C.
SDS-PAGE analysis and fluorescence scanning
Protein samples (recombinant enzyme, cell and tissue homogenate) 
were denatured by adding 5x Laemmli sample buffer containing 2-
mercaptoethanol (1/4
th
of sample volume) and boiling for 4 min at 100°C. 
The samples were then run on a 7.5% or 10% SDS-PAGE gel and wet 
slab gels were scanned for fluorescence using the Typhoon Variable 
Mode Imager (Amersham Biosciences, Piscataway, NJ, USA), using λex
488 nm and λem 520 nm (band pass 40) for green fluorescent ABP 5 and 
λex 532 nm and λem 610 nM (band pass 30) for red fluorescent ABP 3. As 
a loading control, gels were stained with Coomassie Brilliant Blue (CBB) 
and de-stained with milliQ water.
Western blotting
Proteins were transferred onto a PVDF membrane (Bio-Rad Trans-Blot 
Turbo Transfer Pack) using a Bio-Rad Trans-Blot Turbo Transfer System. 
Membranes were blocked with 1% BSA in Tris-buffered saline (TBS) with 
0.1% Tween-20 (TBST) for 1 h at room temperature, hybridized with 
Streptavidin-HRP for 1 h at room temperature (1:10,000 in blocking 
buffer) (Molecular Probes, Life Technologies), washed with TBST and 
TBS and then visualized using an ECL+ western blotting detection kit 
(Amersham Biosciences). Protein standards are PageRuler Plus 
Prestained Protein Ladder (Thermo Scientific) and biotinylated protein 
marker (Bio-Rad).
Proteomics
One kidney from a 5 week old wt mouse was homogenized in 150 mM 
McIlvaine buffer, pH 4.5 supplemented with protease inhibitors. From the 
homogenate 100 µL (containing 3.5 mg protein) were incubated for 2 h at 
37°C with 100 µL of 0.18 mM ABP 4 in 150 mM McIlvaine buffer pH 4.5. 
The analysis was performed as previously reported.
[42]
Peptides were 
desalted on stage tips
[43]
and analyzed with a trap-elute system on C18 
reversed phase nano LC with a 45 min 10-60% ACN/0.1% formic acid 
gradient, hyphenated to a Thermo LTQ-orbitrap mass spectrometer using 
a top 3 data dependent protocol at 60.000 resolution, m/z range 300-
2000, 1000 msec fill time in the Orbitrap, for MS/MS fragmentation 35 
units of CID energy, 120 msec max fill time, AGC 50 e3 and a threshold 
of 750 counts. Ions of z = 2+ and higher were selected to be fragmented 
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twice within 10 sec prior to exclusion for 150 sec. Peak lists were 
extracted and searched against the Uniprot mouse (decoy) database, 
with carbamidomethylation of cysteine as fixed and oxidation of 
methionine as variable modifications, 20 ppm peptide tolerance, trypsin 
as protease and 2 missed cleavages allowed using a Mascot (matrix 
science) search engine.
Fluorogenic substrate assay of recombinant GALC
Culture medium containing recombinant GALC was diluted 2/1 (v/v) with 
McIlvaine buffer pH 4.3 (10 µL total volume) and exposed to the indicated 
concentrations of compounds 1-4 (10 L 2x solution in H2O) for 30 min at 
37°C, before addition of 100 µL substrate mix (0.23 mg/mL 4-
methylumbelliferyl-β-D-galactopyranoside in McIlvaine pH 4.3/H2O 1/1 
(v/v) with 0.2 M NaCl and 0.1% BSA). After incubation at 37°C for 30 min, 
the reaction was quenched with 2.5 mL 0.3 M NaOH-glycine, pH 10.6 
and fluorescence was measured with a fluorimeter LS55 (Perkin Elmer) 
using λex 366 nm and λem 445 nm. All samples were corrected for 
background fluorescence (sample without enzyme) and residual enzyme 
activity was calculated as compared to a control sample incubated in the 
same manner but without inhibitors. Displayed values represent mean 
values from triplicate experiments and error bars indicate standard 
deviation (SD). Graphpad Prism 5 software was used to determine 
apparent IC50 values.
For tests of pH-dependence, culture medium containing recombinant 
GALC was diluted 2/1 (v/v) with McIlvaine buffer pH 4.3 (10 µL total 
volume) and mixed with 100 µL substrate mix of various pH values (0.23 
mg/mL 4-methylumbelliferyl-β-D-galactopyranoside in McIlvaine pH 3 -
pH 8/H2O 1/1 (v/v) with 0.2 M NaCl and 0.1% BSA). After incubation at 
37°C for 30 min, the reaction was quenched and fluorescence measured 
as described above. Displayed values represent mean values from 6 
experiments and error bars indicate standard deviation (SD).
Fluorogenic substrate assay of recombinant α-galactosidase A
Fabrazyme was diluted to a concentration of 0.1 ng/µL in McIlvaine pH 
4.6/H2O 1/1 (v/v) containing 0.1% BSA for stabilization of the 
recombinant protein. A solution of Fabrazyme (1 ng, 20 fmol per 
experiment, 10 µL 0.1 ng/µL) was exposed to the indicated 
concentrations of compounds 1-4 (10 L 2x solution in H2O) for 30 min at 
37°C, before addition of 100 µL substrate mix (1.5 mg/mL 4-
methylumbelliferyl-α-D-galactopyranoside in McIlvaine pH 4.6/H2O 1/1 
(v/v) + 0.1% BSA). After incubation at 37°C for 20 min, the reaction was 
quenched with 2.5 mL 0.3 M NaOH-glycine, pH 10.6 and fluorescence 
was measured with a fluorimeter LS55 (Perkin Elmer) using λex 366 nm 
and λem 445 nm. All samples were corrected for background fluorescence 
(sample without enzyme) and residual enzyme activity was calculated as 
compared to a control sample incubated in the same manner but without 
inhibitors.
In vitro labeling assays using recombinant GALC
In a typical experiment, culture medium containing recombinant GALC (5 
µL) was diluted with McIlvaine buffer pH 4.3/H2O 2/1 (v/v) (14 µL) and 
exposed to the indicated concentrations of ABPs 3 or 4 (1 L 20x 
solution in DMSO) for 1 h at 37°C. Labeling of denatured enzyme was 
performed by pre-heating the enzyme to 100°C for 3 min in buffer with or 
without 1% SDS (9 L total volume) before addition of the probes. One 
half of each sample was resolved on 10% SDS-PAGE. In-gel 
visualization of the fluorescent labeling by probe 3 was performed in the 
wet gel slabs directly. In case of probe 4, biotinylated proteins were 
detected by performing streptavidin western blotting.
Competition assays
Culture medium containing recombinant GALC (5 µL) in McIlvaine buffer 
pH 4.3/H2O 2/1 (v/v) (14 µL) was first exposed for 1 h at 37°C to either 
0.2 µM of 1, 10 µM of 2 or 10 µM of 4 (1 L 20x solution in DMSO), 
before labeling with 0.2 µM 3 (1 L 4 µM in DMSO) as described above.
pH-dependent labeling assay
Culture medium containing recombinant GALC (5 µL) was diluted with 
McIlvaine buffers of pH 3 - pH 8/H2O 2/1 (v/v) (14 µL) and labeled with 
0.5 µM of ABP 3 (1 L 10 M in DMSO) for 1 h at 37°C. Gel bands were 
quantified using Image Lab 4.1 (Bio-Rad) software. Displayed values 
represent mean values (± SD) from 4 independent experiments.
In vitro labeling assays using recombinant GALC and 
glucocerebrosidase
Recombinant glucocerebrosidase (Cerezyme) in McIlvaine buffer pH 
5.2/H2O 1/1 (v/v) (9 µL 0.22 µM, 2.0 pmol, 0.12 µg per experiment) or 
culture medium containing recombinant GALC (2.5 µL) in McIlvaine 
buffer pH 4.3/H2O 2/1 (v/v) (6.5 µL) were exposed to either 1 µM of 
epoxide 3 or 1 µM of epoxide 5
[28]
(1 L 10 µM in DMSO) for 1 h at 37°C. 
The reaction mixtures were then resolved on 7.5% SDS-PAGE and in-gel 
visualization of the fluorescent labeling was performed in the wet gel 
slabs directly.
In vitro labeling assay using mouse tissue homogenates
Animals were first anesthetized with a dose of Hypnorm (0.315 mg/mL 
phenyl citrate and 10 mg/mL fluanisone) and Dormicum (5 mg/mL 
midazolam). The given dose was 80 µL/10 g body weight. Animals were 
sacrificed by cervical dislocation. Tissues were collected, snap frozen in 
liquid N2 and stored at -80°C. Later, homogenates from the frozen 
material were made in 25 mM KPi buffer, pH 6.5, supplemented with 
0.1% (v/v) Triton X-100 and protease inhibitors, and protein 
concentration was determined (BCA kit, Pierce). For labeling 
experiments, a volume of tissue homogenate equivalent to 50 µg (for 
kidney, brain and liver) or 25 µg of protein (for sciatic nerve) was 
completed to 10 µL with water and incubated for 30 min at 37°C with 1 
µM of ABP 3 (10 µL 2 µM in McIlvaine buffer 150 mM pH 4.3) or 100 nM 
of ABP 5 (10 µL 200 nM in McIlvaine buffer 150 mM pH 5.2, 0.2% (w/v) 
sodium taurocholate, 0.1% (v/v/) Triton X-100). The samples were then 
resolved on 7.5% SDS-PAGE and analyzed as described above. For 
competition experiments the indicated concentrations of psychosine (7) 
and ABB166 (6) dissolved in water were pre-incubated with the tissue 
lysate for 30 min on ice before addition of ABP 3 (final concentration 1 
M) and subsequent incubation at 37°C for 15 min.
Fluorogenic substrate assay using mouse tissue homogenates
For measurement of β-galactosidase and β-galactocerebrosidase activity 
we followed the protocol previously described by Martino et al.
[38]
with 
slight alterations. Briefly, a volume of tissue lysate equivalent to 7.5 µg of 
protein was completed with water (6.25 µL total volume) and exposed to 
the indicated concentration of ABP 3 or inhibitor 1 (6.25 µL 2x solution in 
McIlvaine buffer pH 4.3) for 60 min at 37°C. Afterwards 12.5 µL of 110 
µM AgNO3 in water (final concentration 11 µM) and 100 µL of substrate 
mix (0.23 mg/mL 4-methylumbelliferyl-β-D-galactopyranoside in 
McIlvaine pH 4.3) were added and the mixture was incubated for 45 min 
(for β-galactosidase) or 90 min (for GALC) at 37°C. The reaction was 
then quenched with 2.5 mL 0.3 M NaOH-glycine pH 10.6 and the 
fluorescence was measured with a fluorimeter as described above. Data 
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(n = 3 per group) represent mean ± SD. Statistical analysis was 
performed using one-way ANOVA followed by Dunnett´s test.
ABP intracerebroventricular administration
For this purpose, we followed the procedure previously described.
[44]
Briefly, intracerebroventricular stainless steel guide cannulas were 
implanted in the lateral ventricle using the following stereotaxic 
coordinates: AP 0.3, L +1.0 and V -2.2. After a recovery period of 7 days, 
a needle connected to a tube was introduced in the guide cannula and a 
solution of ABP 3 (1 nM in PBS) was administered with a rate of 0.1 
L/min for 10 minutes. After 2 hours, the animals were sacrificed by CO2
euthanasia and transcardially perfused with 250 mL of 0.9% of saline 
solution. Brains were isolated and immediately frozen for further 
biochemical and histological analysis.
Fluorescent and immunohistochemical analysis of brain sections
Brains were cut in 30 m slices with a cryostat and attached to 
SuperFrost slides (Thermo Scientific, Waltham, USA). All following steps 
were performed in the dark to protect the fluorescence of the ABP. Slides 
were extensively washed in 0.01 M TBS to remove non-specific 
fluorescence and were covered in DAPI (Vector Lab, Burlingame, USA) 
mounting media.
For the immunohistological analysis, brain slices were also extensively 
washed in TBS, and next incubated overnight in TBS with 0.5% (v/v) 
Triton X-100, 0.025% (v/v) gelatin and rabbit-raised primary antibodies 
against LAMP1 (Millipore, MA, USA) and GALC (12887-1-AP, 
Proteintech, Chicago, IL, USA) in a concentration of 1:1000. After the 
primary antibody incubation, slides were incubated for 2 h with the 
appropriate secondary antibodies (1:1000) conjugated with fluorescent 
dyes; donkey anti rabbit Alexa 488/Alexa 594 (Life Technologies, Paisley, 
UK). The slides were then rinsed three times with TBS, mounted and 
covered with DAPI to be observed in a confocal laser scanning 
microscope (Leica SP5). Images were made using an excitation 
wavelength of 488 nM for Alexa 488, and 561 nM for Alexa 594 and ABP 
3. For capturing of pictures a 63x objective was used. In the case of 
single cell images a further zoom of 3 times was used.
Fluorescence microscopy
HEK293 cells with and without stable over-expression of murine GALC 
were cultured in glass slides pre-coated with poly-L-lysine. Cells were 
incubated with 5 nM of ABP 3 in the medium for 1 h. Next the cells were 
washed with PBS twice and new medium was added. The cells were 
placed in the incubator overnight (approximately 16 h) before being 
washed again and the glass slides mounted without fixation. For LAMP1 
staining the cells were fixed with 3% paraformaldehyde (v/v) before being 
washed and blocked in donkey serum. Afterwards the cells were stained 
with LAMP1 antibody for 1 h, washed and incubated with the secondary 
Alexa 594-conjugated antibody (see above). The cells were observed 
using a confocal laser scanning microscope (Leica SP5) as described 
previously.
[25]
Fibroblast Concanavalin A affinity purification and ABP labeling
Cell pellets (from T-75cm
2
flasks) of fibroblasts from patients and healthy 
volunteer were lysed in (100 µL) 25 mM KPi buffer, pH 6.5, 
supplemented with 0.1% (v/v) Triton X-100 and protease inhibitors. The 
lysate was incubated overnight at 4°C with 200 µL of pre-washed 
Concanavalin A beads (Sigma-Aldrich). The beads were then washed 
with wash buffer according to manufacturer’s instructions. Bead-bound 
glycoproteins were labeled with 1 µM of ABP 3 in McIlvaine buffer pH 4.3 
for 1 h at 37°C followed by labeling for 30 min with 0.1 µM of ABP 5 in 
McIlvaine buffer 150 mM pH 5.5, 0.2% (w/v) sodium taurocholate, 0.1% 
(v/v/) Triton X-100. The samples were boiled in the presence of 5x 
Laemmli sample buffer and resolved by 10% SDS-PAGE.
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